- Global spending on infusion pumps were $6.4 billion in 2008 which increased to $7 billion in 2009. This is projected to reach $9.6 billion in 2014 at a compound annual growth rate (CAGR) of 6.5%
- Spending alone in USA was nearly $3.3 billion in 2008 which increased to $3.6 billion in 2009. This is projected to reach $4.8 billion in 2014 at a compound annual growth rate (CAGR) of 5.8%
- Spending in Europe was $1.9 billion in 2008, which increased slightly in 2009 to $2 billion. This market is projected to reach approx $2.8 billion in 2014, for a 5-year CAGR of 6.4%.
GLOBAL INFUSION PUMP SPENDING BY GEOGRAPHIC REGION, 2008-2014
Source: BCC Research
Download Report Overview
STUDY GOALS AND OBJECTIVES
BCC’s goal in conducting this study was to determine the current status of the global market for infusion pumps and assess its growth potential over a 5-year period from 2009 to 2014. Of particular interest were changes to the regulatory environment and delivery infrastructure due to healthcare reform in the U.S. and other countries, and the rapid changes in product offerings following a series of high-profile product recalls over the past 2 years.
In addition, BCC was interested in describing the transition to “smart pump” technology and giving an overview of the complex systems that complement and compete with infusion pumps as mode of treatment.
The key objective was to present a comprehensive analysis of the current market for infusion pumps and its future growth prospects in providing safe and effective delivery of medications, nutrients, and analgesics.
REASONS FOR DOING THE STUDY
Almost every aspect of the infusion pump sector is undergoing dramatic change at this time. In response to numerous product recalls, manufacturers have introduced new smart pump technology to reduce Adverse Drug Events (ADEs) and other serious problems associated with previous administrative methods.
Competition from other drug delivery systems, chiefly transdermal and inhaled medicines, may put boundaries on growth for infusion pumps. Demand is growing for continuous administration of medicines and analgesics due to demographic changes in the world’s population and the increasing incidence of diabetes. Ancillary devices such as meters and monitors are becoming a significant force in the market, and design changes have produced new pumps that are smaller, less obtrusive, and have a sense of style, rendering them much more acceptable as ambulatory infusion pumps.
BCC is interested in charting the interplay between these various factors and how they will interact with other changes occurring in the broader landscape of healthcare delivery.
SCOPE OF REPORT
This report covers infusion pumps used for continuous or intermittent administration of medications (including antibiotics), nutrients, and analgesics. BCC analyzes current conditions in the global market and examines the current market condition and variable factors to forecast the future growth of the market. Medical, scientific, technological, social, and economic issues associated with this market are examined. An educated estimate and forecast of growth from 2009 to 2014 are presented by examining the current market and variable factors of each category of diagnostic or therapeutic product.
BCC has compiled a study of the global market for infusion pumps, with an examination of how they interact with other selected drug delivery systems.
We examined current Food and Drug Administration (FDA)-approved medical devices by each category, industry pipelines, and technology innovation through patent protection in the U.S. Patent and Trademark Office (USPTO), the European Patent Office (EPO), and the World Intellectual Property Organization (WIPO), and market competition from transdermal drug-delivery systems and inhaled medications.
Forecasts of the infusion pump market are undertaken by examination of medical and scientific issues, the economic environment, technology innovation, industry pipeline development, market competition, and market growth potential from 2009 to 2014. Market leaders and smaller innovative companies are also introduced.
This study will be of interest to the global pharmaceutical industry, drug and medical device manufacturers, drug and medical device distributors, healthcare maintenance organizations (HMOs) and hospitals, insurance underwriters, government agency regulators, government policy makers, institutional and private investors, and various patient educational communities.
BCC surveyed approximately 45 companies to obtain data for this study. Included were manufacturers of infusion pumps, transdermal drug delivery systems, inhaled medications, glucose monitoring devices, medical device distributors, pharmaceutical manufacturers, and manufacturers of needleless injectors. BCC also spoke with government agency regulators, industry personnel, and medical science personnel. In addition, data was compiled from current financial, legal, trade information, and government sources.
Thomas Fuller has been a market research analyst for 15 years and has published numerous reports on technology products and market issues. Fuller has broad experience in covering regulatory and consumer issues, and currently advises companies on business strategy in the healthcare sector.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
Download Report Overview